Published in
Elsevier, Lancet Haematology, 11(9), p. e833-e843, 2022
DOI: 10.1016/s2352-3026(22)00245-9
Links
Tools
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
Journal article published in 2022 by
Reuben Benjamin,
Deborah Yallop,
Nitin Jain,
Marcela V. Maus,
Nicolas Boissel,
Charlotte Graham 
,
Agnieszka Jozwik,
Marina Konopleva,
Matthew J. Frigault,
Takanori Teshima,
Koji Kato,
Floriane Boucaud,
Svetlana Balandraud,
Athos Gianella-Borradori,
Florence Binlich
and other authors.
,
Agnieszka Jozwik,
Marina Konopleva,
Matthew J. Frigault,
Takanori Teshima,
Koji Kato,
Floriane Boucaud,
Svetlana Balandraud,
Athos Gianella-Borradori,
Florence Binlich
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 